News
Clinical Trials Arena on MSN3d
egnite introduces new research suite to improve patient identification in trialsThe platform's patient-focused outreach is beneficial in navigating the complexities of evolving eligibility criteria for ...
Clinical Trials Arena on MSN3d
Pfizer terminates study of CD47 in blood cancer due to low recruitmentPfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback